-
-
Call more information
660-596-2224 -
The FDA has approved new labeling to highlight the abuse-deterrent properties of extended-release Embeda (morphine sulfate and naltrexone hydrochloride), an oral opioid analgesic indicated for pain that requires daily, 24-hour treatment. “Embeda has properties that are expected to reduce, but not totally prevent, abuse of the drug when crushed and taken orally or snorted,” the […]
Read MoreAs the health insurance industry continues its shift toward a value-based reimbursement system, more payers are experiencing with bundled payments. Though still relatively experiential–of the 11 percent of all value-based reimbursements, just 1.6 percent are bundled payments–the model “has probably the most promise,” Andréa Caballero, program director for Catalyst for Payment Reform said in an […]
Read MoreNever ask for advice when you’re feeling anxious. Take your emotional temperature first. And don’t turn to people who are similar to you when you have a decision to make. 1. We look for advice that will support our original idea Research shows that we all have a tendency to judge the information that comes […]
Read MoreAcupuncture delivered either traditionally through needles or by laser does not significantly improve pain or function at 12 weeks compared with sham acupuncture in older patients with chronic knee pain, new research shows. The study was published in JAMA. Rana Hinman, PhD, from the University of Melbourne, Victoria, Australia, and multicenter colleagues found that neither […]
Read MoreAccording to a new position statement from the American Academy of Neurology (AAN), the risk of death, overdose, addiction or serious side effects with prescription opioids outweigh the benefits in chronic, non-cancer conditions such as headache, fibromyalgia, and chronic low back pain. The position paper is published the journal Neurology. “More than 100,000 people have […]
Read More